OKYO Pharma Gains FDA Alignment, Clearing Path Toward Pivotal Urcosimod Study

OKYO Pharma (NASDAQ: OKYO) reported a successful Type C meeting with the U.S. Food and Drug Administration, marking an important regulatory milestone for its lead candidate urcosimod in the treatment of neuropathic corneal pain (NCP) — a chronic and debilitating eye condition with no FDA-approved therapies.

The meeting resulted in FDA alignment on key elements of OKYO’s proposed Phase 2b/3 clinical trial, including study design, primary efficacy endpoint, sample size assumptions, and statistical framework. The agency also raised no material concerns around manufacturing or development strategy, effectively de-risking the regulatory pathway as the company advances toward a late-stage program.

A Clearer Development Path Emerges

With FDA feedback in hand, OKYO plans to initiate a 120-patient, randomized, multiple-dose Phase 2b/3 trial in the first half of 2026. The study is designed to evaluate urcosimod’s ability to reduce pain severity using a clinically meaningful endpoint, while also capturing quality-of-life measures that reflect real-world patient benefit.

For investors, regulatory alignment at this stage is particularly meaningful. Agreement on endpoints and trial structure reduces uncertainty around future approval requirements and increases confidence that positive data could support a registration filing.

Why This Matters for Investors

Neuropathic corneal pain represents a significant unmet medical need, and OKYO’s program targets a patient population with limited treatment options. The FDA’s support for the proposed trial design reinforces the relevance of the chosen endpoint and strengthens the commercial thesis should the therapy demonstrate efficacy.

From a valuation perspective, the update shifts OKYO into a more defined catalyst-driven phase, with a visible path toward pivotal data generation. As a result, investor focus is likely to move toward execution, trial initiation timelines, and eventual clinical readouts.

Building on Prior Clinical Signals

The upcoming study builds on earlier clinical data that showed encouraging signals of pain reduction and improvements in corneal nerve parameters. While those results were exploratory, they provided the foundation for the current development plan and helped inform discussions with regulators.

With FDA expectations now clarified, OKYO can advance urcosimod with greater precision and reduced regulatory risk — an important inflection point for a small-cap clinical-stage biotech.

Bottom Line

OKYO Pharma’s successful FDA Type C meeting represents a meaningful de-risking event that brings structure and clarity to the company’s late-stage development strategy. With a Phase 2b/3 study planned and regulatory alignment secured, the company enters a critical execution phase that could define its long-term value.

For investors tracking OKYO, the focus now shifts from regulatory uncertainty to clinical delivery, with upcoming trial initiation serving as the next key catalyst.